Tag - MATN

Developments

Mateon gets FDA rare pediatric disease designation for melanoma drug candidate

Mateon Therapeutics’ (NASDAQ:MATN) CA4P received FDA pediatric disease designation for the treatment of stage 2b-to-4 melanoma due to genetic mutations that disproportionately affect pediatric patients. As a single...

May 6, 2020

Developments

Mateon Therapeutics gets FDA pediatric disease designation for DIPG drug candidate

Mateon Therapeutics’ (NASDAQ:MATN) OT-101 received FDA pediatric disease designation for the treatment of diffuse intrinsic pontine glioma (DIPG). DIPG is a rare pediatric brainstem tumor that has a very low survival...

September 24, 2019

Feature

Mateon taking VDAs in new direction against cancer

By Len Zehr Mateon Therapeutics (NASDAQ:MATN) is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal tumor blood vessels, which supply nutrients to cancer cells, with an initial clinical focus...

September 13, 2016

Tag - MATN

Mateon gets FDA rare pediatric disease designation for melanoma drug candidate

Mateon Therapeutics gets FDA pediatric disease designation for DIPG drug candidate

Mateon taking VDAs in new direction against cancer

General

More